- Drugs
- Wednesday, 15 Jul 2020
AstraZeneca ties up with IQVIA to speed up studies of COVID-19 vaccine candidate
Life sciences company IQVIA Holdings Inc said on Tuesday it would collaborate with AstraZeneca Plc to speed up clinical studies of the British drugmaker’s potential COVID-19 vaccine in the United States.
The collaboration is part of the U.S. government’s Operation Warp Speed to accelerate the development of COVID-19 vaccines and treatments.
AstraZeneca is among the drugmakers farthest along in the race to develop a safe and effective vaccine for COVID-19, the respiratory disease caused by the new coronavirus. The British drugmaker has received U.S. funding of more than $1 billion to secure access to dosages.
The agreement includes an expansive study of trial participants and will use IQVIA’s virtual trial solutions that would make parts of the study remote.
Clinical trial service providers like IQVIA have seen a boost in demand for their offerings in virtual care - an area that has been slow to catch on - as the pandemic forces people to self-isolate and stay at home.
Related Industry Updates
Fluorine-18 Market is expected to reach US$ 2.41billion by 2030
Feb 06, 2024
Acute Pancreatitis Market is expected to reach US$ 8,827.37 million by 2030
Sep 08, 2023
Pharmaceutics International Selected as A Winner of Two GH&P Awards
May 04, 2020
GSK sells $3.35 billion stake in Unilever’s Indian business
May 07, 2020
UnitedHealth rises on 'minimal' COVID-19 impact on results & maintained its forecast
Apr 15, 2020
Impairment of Cannabis in Safety Sensitive Positions
Oct 21, 2019
Verde Leaf™ Appoints Carl L. Powell as Chairman
May 05, 2020
Follow us on
